Has Michael Anderson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $35,905 in general payments to Michael Anderson, MD across 274 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Anderson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Anderson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Anderson, MD

Radiation Oncology · Henderson, NVNPI 1316916182

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (39.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by Bayer at 31.7% of the total. Reporting peaked in 2020 at $16,365 and has fallen 83.8% since, to $2,657 in 2025. Among radiation oncology clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$35,905in general payments, 2019–2025

Across 274 payments — averaging $131.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bayer$11K
Novocure Inc.$11K
AstraZeneca$7K
Regeneron Healthcare Solutions, Inc.$1K
Daiichi Sankyo Inc.$1K
Novartis$381
plus $3K from 40 others

$45,791in research payments, 2019–2025

Across 26 payments — averaging $1761.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novocure Inc.$39K
Novartis$7K

What the payments were for

Consulting fees$11,65532%
Speaking & faculty fees$14,05539%
Travel & lodging$1,9485%
Food & beverage$8,14423%
Education$240%
Entertainment$790%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bayer	7	$11,399
Novocure Inc.	23	$11,109
AstraZeneca	16	$7,040
Regeneron Healthcare Solutions, Inc.	29	$1,457
Daiichi Sankyo Inc.	91	$1,280
Novartis	15	$381
Incyte Corporation	7	$341
Hologic Inc	1	$211
Telix Pharmaceuticals	3	$206
Visionrt, Inc.	1	$199
Merck	7	$157
Progenics Pharmaceuticals, Inc.	3	$138
Karyopharm Therapeutics Inc.	4	$132
Icotec Medical Inc.	1	$124
Gilead	1	$124
Monteris Medical Corporation	2	$122
Exelixis Inc.	4	$112
Genentech USA, Inc.	5	$108
Pfizer	4	$95
Johnson & Johnson	5	$91
Mirati Therapeutics, Inc.	4	$88
Keystone Dental Inc.	1	$79
Amgen	4	$74
Takeda Pharmaceuticals U.S.A., Inc.	3	$70
GSK	3	$69
Sobi, Inc	3	$67
Dendreon Pharmaceuticals LLC	2	$56
Beigene USA, Inc.	2	$53
CSL Behring	2	$50
Genmab U.S., Inc.	2	$48
Tempus AI, Inc	2	$45
Bristol Myers Squibb	2	$40
Advanced Accelerator Applications	1	$40
Sumitomo Pharma America, Inc.	2	$39
Sanofi	1	$36
EMD Serono, Inc.	1	$25
Coherus Oncology, Inc.	1	$25
Myovant Sciences Inc.	1	$24
Pharmacyclics LLC, An Abbvie Company	1	$23
Taiho Oncology, Inc.	1	$22
Stemline Therapeutics Inc.	1	$20
Rigel Pharmaceuticals, Inc.	1	$19
Eisai Inc.	1	$18
Geron Corporation	1	$18
Octapharma USA, Inc.	1	$17
Seagen Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,905 in reported general payments places this provider in the 90th percentile of 47 radiation oncology providers in Nevada.

See all radiation oncology providers in Nevada →

Medicare billing

Part B allowed, 2024

$1,330,586

Medicare patients

380

Services billed

27,789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Mometasone Furoate	16	$337

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Henderson

Matthew SchwartzHenderson$169K
Paul TreadwellHenderson$108
Guy JonesReno$57K
Garrett GreenReno$37K
Jason KehrerReno$27K
Farzaneh FarzinLas Vegas$12K
Samual FrancisLas Vegas$10K
Ritchie StevensLas Vegas$9K
Anita PomerantzLas Vegas$9K
Michael SinopoliLas Vegas$5K

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →